K-NK004 / Sanofi - LARVOL DELTA

CD38KO K-NK cells prevent NK cell fratricide effect and improve isatuximab-mediated cytotoxicity against multiple myeloma cells (AACR 2022) - "CD38 is highly expressed on MM cells, and antibodies targeting CD38 (such as Isatuximab and Daratumumab) induce MM cell killing though several mechanisms, particularly by NK cell-mediated antibody dependent cellular cytotoxicity (ADCC). Indeed, addition of SAR444245 was found to further enhance the cytotoxic activity of CD38KO K-NK cells against LP-1 MM cells when combined with Isatuximab, resulting in an overall superior and sustained cytotoxicity. These data suggest that deletion of CD38 mitigates NK cell fratricide and improves Isatuximab-mediated ADCC against MM cells, and provide evidence for the therapeutic potential of the triple combination CD38KO NK cells, Isatuximab and SAR444245 in the setting of MM."

Hematological Malignancies • Multiple Myeloma • Oncology • IL2 • NKG2D

"@JacobPlieth wrote about $SNY and Kiadis partnership in July 2020, and Kiadis K-NK004’s competitor $FATE FT538 and FT576. https://t.co/1EqWFGrsrV" (@jq1234t)

Licensing / partnership

Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma (Pharmaceutical-technology.com) - "Netherlands-based Kiadis Pharma has licensed one of its four natural killer (NK) cell therapy programmes to French pharma giant Sanofi. The programme in question is known as K-cand focuses on multiple myeloma...According to the terms of the deal, Kiadis will receive €17.5m upfront from Sanofi, and be eligible for up to €857.5m in potential milestone payments."

Licensing / partnership • Hematological Malignancies • Multiple Myeloma • Oncology

Kiadis announces publication in Blood highlighting proof-of-concept to enhance potency of anti-CD38 antibodies with Kiadis’ K-NK004, recently licensed by Sanofi (GlobeNewswire) - "Kiadis Pharma...today announces publication of an article in Blood, Journal of the American Society of Hematology. The article describes the synergy of mbIL21 expanded NK cells (FC21-NK) modified with a CD38 gene knockout together with an anti-CD38 monoclonal antibody (mAb) for enhanced killing of multiple myeloma cells...the use of the CRISPR/Cas9 system to delete CD38 (CD38KO) in ex vivo expanded peripheral blood K-NK cells, with 82% knock out efficiency..."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology